Rationale and Design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): a Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects After Acute Myocardial Infarction